Product Data Sheet

Pergolide mesylate



Cat. No.:	B1485
CAS No.:	66104-23-2
Formula:	C19H26N2S·CH4O3S
M.Wt:	410.59
Synonyms:	
Target:	Neuroscience
Pathway:	Dopamine Receptor
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

insoluble in EtOH; insoluble in H2O; ⩾6.84 mg/mL in DMSO

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.4355 mL	12.1776 mL	24.3552 mL
5 mM	0.4871 mL	2.4355 mL	4.8710 mL
10 mM	0.2436 mL	1.2178 mL	2.4355 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Dopaminergic agonist
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	SH-SY5Y neuroblastoma cell
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	10 nM to 50 μM

	Applications:	Pergolide dose-dependently protected neuroblastoma cells from H2O2-induced neurotoxicity with IC50 values of pergolide of about 40 and 60 nM. Incubation of the cells with 1 μM pergolide for 26 h did not affect cell viability. Preincubation of the cells with 100 nM pergolide for 2 h before the cytotoxic agent did not affect the neurotoxic effect of either doxorubicin or cis-platinum.
In Vivo	**Animal experiment**	
	Animal models:	Female rats
	Dosage form:	Intraperitoneal injection, 0.5 mg/kg/day, 7 days
	Applications:	In spayed female rats, pergolide mesylate significantly suppressed food intake and body weight. Inhibition of food intake by a constant dose of pergolide progressively diminished with repeated administrations. Pergolide suppressed body weight with no indications of tolerance. In rats treated with pergolide mesylate (7 days 0.5 mg/kg/day, i.p.), the average amount of 2,3-DHBA associated with 6-OHDA striatal infusion was significantly smaller than that in controls. Pergolide treatment led to an increased ability of striatal tissue to quench hydroxyl radical formation in vivo.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Uberti D, Piccioni L, Colzi A, et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H 2 O 2[J]. European journal of pharmacology, 2002, 434(1): 17-20.

[2]. Greene S B, Mathews D, Hollingsworth E M, et al. Behavioral effects of pergolide mesylate on food intake and body weight[J]. Pharmacology Biochemistry and Behavior, 1985, 23(2): 161-167.

[3]. Opacka-Juffry J, Wilson A W, Blunt S B. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum[J]. Brain research, 1998, 810(1): 27-33.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com